Cancer prevention research (Philadelphia, Pa.)最新文献

{"title":"Determinants of cervical cancer screening acceptance among women in urban and tribal communities of Maharashtra, India: a cross-sectional study.","authors":"Kiran Munne, Prerana Patil, Anjali Mayekar, Shantanu Birje, Ganga Bhekare, Shahanara Prabhu Valawalkar, Anamika Akula, Varsha Tryambake, Sharmila Kamat, Rachana Dalvi, Deepti Tandon, Suchitra Surve, Shahina Begum, Madhuri Shikhare, Sharmila Pimple, Anushree Patil","doi":"10.1158/1940-6207.CAPR-25-0174","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-25-0174","url":null,"abstract":"<p><p>Although screening, treatment and HPV vaccination can prevent cervical cancer, 17.7% new Indian cases were still recorded in 2022. Illiteracy, undesirable attitudes, and ineffective screening services undermine the effectiveness of cervical cancer screening. We evaluated the knowledge (K), attitude (A) and practices (P) towards cervical cancer and their influence on screening acceptance among urban and tribal women of Maharashtra, India. A cross- sectional study was conducted among 500 urban and 500 tribal women, recruited to equally represent both populations. KAP data on cervical cancer was collected using a structured questionnaire. Participants received free cervical cancer screening. KAP scores were calculated, and their associations with sociodemographic factors and cervical cancer screening were assessed using logistic regression. Total 939 participants were enrolled. Considering both populations, total 530 (56%) participants were unaware about cervical cancer, 296 (72%) about its symptoms and 250 (61%) of risk factors. Common misconceptions were that only women with symptoms of cervical cancer (166, 18%), or a family history of cervical cancer (385, 41%) needed screening. Fear of pain, bad result and embarrassment were major perceived barriers. While 65 (6.85%) participants had previously undergone screening, 756 (81%) desired screening and 670 (71.40%) underwent screening. Although women had limited cervical cancer knowledge, their attitude for screening is favorable. Generating awareness and implementing socioculturally acceptable strategies is crucial for amplifying cervical cancer screening among vulnerable women.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Murine Models of Obesity-Related Cancer Risk.","authors":"Lukmon M Raji, Monowarul M Siddique, Margaret S Bohm, Joseph F Pierre, Mary C Playdon, Scott A Summers, Bing Li, Katherine L Cook, E Angela Murphy, Liza Makowski","doi":"10.1158/1940-6207.CAPR-24-0545","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-24-0545","url":null,"abstract":"<p><p>Obesity is a global menace that has impacted over 14% of adults worldwide and over a third of Americans. Importantly, obesity is associated with an increased risk of over 13 types of cancer and worse outcomes, including increased mortality. This review focuses on the importance of considering obesity and metabolic dysfunction in cancer risk as part of the National Cancer Institute's funded consortium known as the Metabolic Dysfunction and Cancer Risk Program (MeDOC). It describes previous and ongoing mouse models used in studies conducted by MeDOC consortium members, as well as other relevant studies. Most cancer studies examine tumor progression, metastasis, or recurrence, which are consequences following tumor onset; however, this approach does not consider risk per se. To truly model cancer risk, parameters to measure include the quantification of cancer onset, measured as incidence or latency. Investigators must be cognizant of many factors in study design, including the choice of cancer model and genetic strain. Preclinical approaches addressing risk typically include genetically engineered mouse models or the administration of irritants or carcinogens. We also discuss the transplantation of cells or tumors such as allografts or xenografts, with a focus on tumor rejection or regression to approximate cancer risk, not cancer progression. Herein, we highlight two cancers, breast and colorectal cancer, where risk is associated with obesity and discussed varied murine model approaches, as well as key findings that explore cancer risk, prevention, or interception.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention.","authors":"Xiangzhu Zhu, Ruohui Chen, Reid M Ness, Rishi D Naik, Harvey J Murff, Heping Zhang, Yanfei Xu, Kelly A Benante, M Andrea Azcarate-Peril, Yinan Zheng, Jun Wang, Martha J Shrubsole, Timothy Su, Xinlei Mi, Masha Kocherginsky, Luz Maria Rodriguez, Gary Della'Zanna, Ellen Richmond, Lifang Hou, Seema A Khan, Qi Dai","doi":"10.1158/1940-6207.CAPR-24-0168","DOIUrl":"10.1158/1940-6207.CAPR-24-0168","url":null,"abstract":"<p><p>Aspirin reduces colorectal cancer risk but has a potential for adverse effects. Recent preclinical data suggest that intermittent dosing of aspirin may minimize adverse effects while maintaining efficacy. We conducted a three-arm double-blind randomized placebo-controlled phase II trial. The primary objective of the study was to test for the equivalency of two aspirin schedules, i.e., the effects of daily aspirin 325 mg/day continuously (cont-ASA) for 12 weeks or intermittently and 3 weeks on/3 weeks off on biomarkers related to colorectal carcinogenesis in rectal mucosa. A placebo group enabled the estimation of spontaneous biomarker variation. Eighty-one participants were randomized, of whom forty-five were evaluable. For the primary endpoint of decrease in the Ki-67:BCL2-associated X ratio, we could not establish equivalence for the two treatment regimens and also found no significant difference between them. For the secondary endpoint, cont-ASA treatment was significantly more effective in reducing the Ki-67:terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling ratio. Among exploratory endpoints, we found more reduction in epithelial COX-2 expression in the cont-ASA arm compared with the intermittent aspirin dosing arm. We did not observe significant differences in other secondary and exploratory endpoints. Intermittent aspirin dosing in 3-week cycles does not produce the same biologic effect as continuous dosing. Future studies should examine whether a 1-week on/1-week off schedule can maximize the efficacy and minimize the side effects. Prevention Relevance: In this three-arm double-blind randomized placebo-controlled phase II trial, we could not establish equivalence for daily aspirin 325 mg versus intermittent aspirin (3 weeks on/3 weeks off) on Ki-67:BCL2-associated X ratio. However, compared with intermittent aspirin administration, continuing aspirin was significantly more effective in reducing the Ki-67:terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling ratio and COX-2 in rectal mucosa.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"321-334"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of the Newly Eligible Population under Two Recent Updates of Lung Cancer Screening Recommendations.","authors":"Yu Liu, Michael T Halpern, Robert J Volk, Ya-Chen Tina Shih","doi":"10.1158/1940-6207.CAPR-24-0465","DOIUrl":"10.1158/1940-6207.CAPR-24-0465","url":null,"abstract":"<p><p>The United States Preventive Services Task Force updated its lung cancer screening (LCS) recommendations in 2021, and the American Cancer Society (ACS) updated its LCS guidelines in 2023. Each update expanded screening eligibility criteria, thus increasing the total number of individuals eligible for LCS. However, it is not clear whether different population subgroups benefit equally from the recent updates of LCS recommendations in terms of becoming newly eligible. We identified 85,395 individuals who were between 50 and 80 years old, smoked cigarettes formerly or currently, and did not have a history of lung cancer from the Behavioral Risk Factor Surveillance System survey of 2022. We used descriptive analysis to illustrate the weighted proportions of the newly screening-eligible population among different subgroups. We also applied multivariable logistic regression models to estimate the ORs of being newly eligible for LCS under each LCS recommendation update in 2021 and 2023. For both LCS updates, individuals who were non-Hispanic White males and had chronic obstructive pulmonary disease were significantly more likely to become newly eligible for LCS. A significantly larger proportion of older-age individuals became newly eligible under the 2023 ACS guideline. Noticeably, both guideline updates substantially increased the population eligible for screening among males and older individuals, two groups experiencing the majority of lung cancer incidence and mortality. Results also indicate that the screening eligibility criteria updates did not increase the OR of being eligible among racial/ethnic minority and female subgroups. Prevention Relevance: This study examines the evolving LCS guidelines and their public health impact. Analyzing the 2021 United States Preventive Services Task Force and 2023 ACS updates, we show expanded eligibility but persistent disparities among sociodemographic groups. Our findings highlight the need for targeted interventions to improve screening uptake and promote equitable, inclusive prevention strategies.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"365-373"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deriving a Mammogram-Based Risk Score from Screening Digital Breast Tomosynthesis for 5-Year Breast Cancer Risk Prediction.","authors":"Shu Jiang, Debbie L Bennett, Graham A Colditz","doi":"10.1158/1940-6207.CAPR-24-0427","DOIUrl":"10.1158/1940-6207.CAPR-24-0427","url":null,"abstract":"<p><p>Screening digital breast tomosynthesis (DBT) aims to identify breast cancer early when treatment is most effective, leading to reduced mortality. In addition to early detection, the information contained within DBT images may also inform subsequent risk stratification and guide risk-reducing management. Using transfer learning, we refined a model in the Joanne Knight Breast Health Cohort at Washington University, a cohort of 5,066 women with DBT screening (mean age, 54.6), among whom 105 were diagnosed with breast cancer (26 ductal carcinoma in situ). We applied the model to external data from the Emory Breast Imaging Dataset, a cohort of 7,017 women free from cancer (mean age, 55.4), among whom 111 pathology-confirmed breast cancer cases were diagnosed more than 6 months after initial DBT (17 ductal carcinoma in situ). We obtained a 5-year AUC of 0.75 [95% confidence interval (CI), 0.73-0.78] in the internal validation. The model validated in external data gave an AUC of 0.72 (95% CI, 0.69-0.75). The AUC was unchanged when age and Breast Imaging-Reporting and Data System density were added to the model with synthetic DBT images. The model significantly outperforms the Tyrer-Cuzick model, with a 5-year AUC of 0.56 (95% CI, 0.54-0.58; P < 0.01). Our model extends risk prediction applications to synthetic DBT, provides 5-year risk estimates, and is readily calibrated to national risk strata for clinical translation and guideline-driven risk management. The model could be implemented within any digital mammography program. Prevention Relevance: We develop and externally validate a 5-year risk prediction model for breast cancer using synthetic DBT and demonstrate clinical utility by calibrating to the national risk strata as defined in breast cancer risk management guidelines.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"347-354"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12127798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Screening Progress and Noninvasive Screening Opportunities since the Onset of the COVID-19 Pandemic.","authors":"John M Carethers","doi":"10.1158/1940-6207.CAPR-25-0007","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-25-0007","url":null,"abstract":"<p><p>Cancer screening lowers morbidity and mortality from cancer and is cost-effective. The COVID-19 pandemic upended cancer screening utilization in 2020 with data showing a deficit in screened patients in 2020 and 2021 as compared with 2019, with return to 2019 baseline screening levels by December 2022. The cumulative shortfall in screenings, lasting nearly 3 years into the pandemic, is predicted by models to generate an incremental population cancer burden in the out-years of the models. Recovery of screening rates may vary based on the racial or ethnic population, and time will tell if there is an uneven burden of future cancers that worsen cancer incidence and mortality in those populations, some even after years of gains of reducing disparities for cancer screening. For some cancer screenings, particularly cervical and colorectal cancers, use of at-home noninvasive tests may increase screening participation overall across multiple populations and help mitigate some of the screening shortfalls from 2020 to 2022 by elevating numbers of the population screened. For colorectal cancer, new additional comparably sensitive or ease-of-use noninvasive screening tests are being added for utilization.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":"18 6","pages":"313-319"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower Neighborhood-Level Socioeconomic Status Is Associated with Lower Colorectal Cancer Screening Uptake in the Southern Community Cohort Study.","authors":"Lauren Giurini, Ronald E Gangnon, Amy Trentham-Dietz, Wei Zheng, Loren Lipworth, Harvey J Murff, Mark Steinwandel, Jennifer Weiss, Shaneda Warren Andersen","doi":"10.1158/1940-6207.CAPR-24-0541","DOIUrl":"10.1158/1940-6207.CAPR-24-0541","url":null,"abstract":"<p><p>Colorectal cancer is highly preventable with timely screening, but screening modalities are widely underused, especially among those of low individual-level socioeconomic status (SES). In addition to individual-level SES, neighborhood-level SES may also play a role in colorectal cancer screening completion through less geographic access to health care, transportation, and community knowledge of and support for screenings. We investigated the associations of neighborhood SES using a census tract-level measure of social and economic conditions with the uptake of colonoscopy and stool-based testing. We utilized data from the Southern Community Cohort Study, a large, prospective study of English-speaking adults ages 40 to 79 from the southeastern United States with 65% of participants identifying as non-Hispanic Black and 53% having annual household income <$15,000. Neighborhood SES was measured via a neighborhood deprivation index compiled from principal component analysis of 11 census-tract variables in the domains of education, employment, occupation, and poverty; screening was self-reported at the baseline interview (2002-2009) and follow-up interview (2008-2012). We found that participants residing in the lowest SES areas had lower odds of ever undergoing colonoscopy (ORQ5vsQ1 = 0.75; 95% confidence interval, 0.68-0.82) or stool-based colorectal cancer testing (ORQ5vsQ1 = 0.71; 95% confidence interval, 0.63-0.80) while adjusting for individual-level SES factors. Associations were consistent between neighborhood SES and screening in subgroups defined by race, sex, household income, insurance, or education (P > 0.20 for all interaction tests). Our findings suggest that barriers to screening exist at the neighborhood level and that residents of lower SES neighborhoods may experience more barriers to screening using colonoscopy and stool-based modalities. Prevention Relevance: This study presents evidence that persons living in lower SES neighborhoods use colorectal cancer screening modalities at lower rates. Screening is highly preventive of colorectal cancer, but it has limited benefit if it cannot be utilized. Addressing neighborhood-level barriers to screening may improve socioeconomic disparities in colorectal cancer.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"355-363"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized Phase II Clinical Trial of Sulforaphane in Former Smokers at High Risk for Lung Cancer.","authors":"Jian-Min Yuan, Thomas W Kensler, Sanja Dacic, Douglas J Hartman, Renwei Wang, Paula A Balogh, Pamela Sufka, Melissa A Turner, Kimberly Fuhrer, Lindsey Seigh, Yen Thi-Hai Pham, Jennifer Adams-Haduch, Giuseppe Valacchi, Shivendra V Singh, James G Herman, David O Wilson","doi":"10.1158/1940-6207.CAPR-24-0386","DOIUrl":"10.1158/1940-6207.CAPR-24-0386","url":null,"abstract":"<p><p>Experimental studies have shown that dietary isothiocyanates reduced cellular proliferative marker Ki-67 and increased apoptotic markers caspase-3 and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) in animals, but human data are lacking. The present study was to assess whether sulforaphane would stop/reverse the progression of bronchial histopathology, reduce the Ki-67 index, and/or increase caspase-3 and TUNEL indices in humans. A randomized clinical trial (NCT03232138) was conducted in former smokers. Forty-three subjects were randomly assigned to the placebo or the treatment with a potential daily dose of 95 μmol sulforaphane for 12 months. The endpoints were the changes in histopathology scores and Ki-67, caspase-3, and TUNEL indices in post- versus pretreatment bronchial biopsies. Thirty-seven participants (17 in the sulforaphane and 20 in the placebo group) completed the study. Supplementation of sulforaphane did not show significant impact on bronchial histopathology but significantly reduced the Ki-67 index with a 20% decrease in the sulforaphane group and a 65% increase in the placebo (P = 0.014). The difference was even greater in high-density (3+) positive Ki-67, with a 44% decrease in the sulforaphane group compared with a 71% increase in the placebo (P = 0.004). Higher bioavailability of sulforaphane was correlated with greater reduction of the Ki-67 index (P for trend = 0.019). Sulforaphane treatment had no impact on the caspase-3 or TUNEL index in bronchial biopsies. No severe adverse event was observed in the study participants. The findings of oral sulforaphane that significantly reduced the Ki-67 index in bronchial tissue support further development as a potential chemopreventive agent against lung cancer development. Prevention Relevance: High intake of cruciferous vegetables and their sulforaphane is associated with lower incidence of lung cancer in humans and animal models. This clinical trial has demonstrated that oral supplementation of sulforaphane for 12 months significantly reduced the Ki-67 index, a potential surrogate endpoint of biomarkers for lung cancer risk.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"335-345"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CervicalMethDx: a precision DNA methylation test to identify risk of high-grade intraepithelial lesions in cervical cancer screening algorithms.","authors":"Laura Palmieri, Fernando T Zamuner, Dieila Giomo de Lima, Keerthana Gosala, Eli Winkler, Yash Prashar, Ana Purcell-Wiltz, Amanda García-Negrón, Ashley Ramos-Lopez, Josefina Romaguera, Bruce J Trock, Teresa Díaz-Montes, David Sidransky, Mariana Brait, Rafael Guerrero-Preston","doi":"10.1158/1940-6207.CAPR-25-0029","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-25-0029","url":null,"abstract":"<p><p>Cervical cancer is one of the most common cancers in women. Despite progress in prevention and success in early detection through cytologic screening and Human Papilloma Virus (HPV) detection, there remains a challenge in triaging women appropriately to colposcopy and biopsy. We sought to validate the CervicalMethDx test, a precision DNA methylation classifier for cervical cancer detection, as a reflex test in women with HPV positive samples. A blinded retrospective study was performed on well-characterized samples in PreservCyt media from a large referral clinical laboratory in the United States. DNA methylation was assessed in three gene promoters (ZNF516, FKP6 and INTS1) and a control gene (B-actin) by quantitative Real Time Methylation Specific PCR (qMSP) analysis, using machine learning algorithms. We compared DNA methylation levels in HPV positive patients presenting with lesions in the Pap test and CIN2 or CIN3 histological diagnosis, to DNA methylation levels in HPV positive patients with lesions in the Pap test, but no Intraepithelial Lesions or Malignancy (NILM). CervicalMethDx test correctly classified 95% of the CIN2 samples (n=210), with 91% Sensitivity, 100% Specificity, and an AUC of 0.96, and 94% of CIN3 samples (n=141), with 90% Sensitivity, 100% Specificity, and an AUC of 0.96. Moreover, the CervicalMethDx test correctly classified 94% of combined CIN2/CIN3 samples (n=351), with 93% Sensitivity, 97% Specificity, and an AUC of 0.96. CervicalMethDx demonstrated strong discriminatory power for identifying CIN2/3 risk and may complement current triage strategies for colposcopy referral. Prospective, population-based studies, including low-resource settings, are needed for further evaluation.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight Loss Is Protective in Preclinical Breast Cancer Models: Interactions with the Anticancer Immune Response.","authors":"Rachel R Sassoon, Rachel J Perry","doi":"10.1158/1940-6207.CAPR-25-0168","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-25-0168","url":null,"abstract":"<p><p>Growing research suggests that advanced aging and obesity are correlated with an increased risk and poorer prognosis in triple-negative breast cancer. In this issue of Cancer Prevention Research, Smith and colleagues fed young and old mice a control/low-fat diet, a high-fat diet, or an intermittent calorie restriction (ICR) diet prior to injection of E0771 breast cancer cells. The ICR mice exhibited lower rates of tumor growth across all interventions, with tumor size in ICR mice matched to that of young, lean controls. Most notably, the authors found that ICR mice also exhibited the highest antitumor immunity. These data provide encouraging preclinical evidence that immune dysfunction induced by obesogenic diets is reversible. See related article by Smith et al., p. XX.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"OF1-OF2"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}